Constellation Pharmaceuticals, Inc.
CNST
CNST was delisted on the 14th of July, 2021.
134 hedge funds and large institutions have $1.46B invested in Constellation Pharmaceuticals, Inc. in 2020 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 36 increasing their positions, 42 reducing their positions, and 21 closing their positions.
76% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 21
48% more capital invested
Capital invested by funds: $990M → $1.46B (+$471M)
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
13% more funds holding
Funds holding: 119 → 134 (+15)
14% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 42
41% less call options, than puts
Call options by funds: $1.55M | Put options by funds: $2.61M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$46.6M |
| 2 |
Morgan Stanley
New York
|
+$27.1M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$23.4M |
| 4 |
CC
Casdin Capital
New York
|
+$20.3M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$18.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$46.2M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$33.4M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.9M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$21.9M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$20.8M |
CNST Hedge Fund Activity: Q4 2020 in Review
134 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q4 2020, worth a combined $1.46B — up 48% from $990M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new CNST positions and 21 closed out — a net gain of 16 holders — while 36 added to existing stakes and 42 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $46.6M. The largest seller was Great Point Partners, cutting an estimated $46.2M.
- 134 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q4 2020, up from 119 in Q3 2020.
- Funds reported $1.46B of Constellation Pharmaceuticals, Inc. stock for Q4 2020, up 48% quarter-over-quarter.
- 37 funds opened new Constellation Pharmaceuticals, Inc. positions in Q4 2020 and 21 closed out, a net change of +16 holders.
- The largest Constellation Pharmaceuticals, Inc. buyer in Q4 2020 was RA Capital Management, an estimated $46.6M added.
- The largest Constellation Pharmaceuticals, Inc. seller in Q4 2020 was Great Point Partners, an estimated $46.2M sold.
Based on aggregated 13F filings for Q4 2020.